Reckitt Benckiser Group plans to invest about $400 million in the U.S. over the next four years, building on a $200 million commitment made in 2024. The U.K.-based consumer-goods company said the additional spending will accelerate product innovation, strengthen its supply chain against disruptions and improve its ability to meet sudden increases in consumer demand. Reckitt bought a factory in Wilson, N.C., in 2024 to shift some Mucinex cough and cold medicine production from Mexico and the U.K. to the U.S.